en · de · es · fr · pt
aod-9604-notes.peptides4088.com › Topic › Research And Regulatory Status — Evidence Review

Research And Regulatory Status — Evidence Review

By Editorial Desk · published 2026-07-06 · last reviewed 2026-07-22 · Topic

hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-07-22. Numbers and descriptions here follow the published literature rather than marketing material.

Research and Regulatory Status

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Background and Development History

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Aod-9604 at a glance

PropertyValueNotes
Primary research areaObesity and metabolic regulationStudied in cell, animal, and human models
Highest reported trial phasePhase IIPublic summaries describe mixed results
Common route in trialsSubcutaneous injectionTypical for peptide therapeutics
Regulatory example2013 Australian anti-doping reviewClassification was debated at the time
Approval statusNot approved as a human medicineStatus can change by jurisdiction

Measurement and Storage Practices

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Related pages on this site

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Mechanism and Regulatory Status

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Background from the literature

polymerization The formation of a polymer from its constituent monomers; the chemical reaction or series of reactions by which monomeric subunits are covalently linked together into a polymeric chain or branching aggregate; e.g. the polymerization of a nucleic acid chain by linking consecutive nucleotides, a reaction catalyzed by a polymerase enzyme.

== Structure and bonding == Most organomercury compounds feature diamagnetic Hg(II) and adopt a linear C−Hg−X structure. Indeed, no organic derivatives of Hg2+2 are known, as Hg2+2 requires electronegative substituents for condensed-phase stability. Hg(II) derivatives are neither Lewis basic or Lewis acidic. They are stable to oxygen and water, indicating the low polarity of the Hg−C bond. The structure of "mercurocene" is instructive. When made in the 1950s, it was too sensitive for structural determination. Later analysis determined that the products have the mercury σ-bonded to just one carbon of each ring, rather than a metallocene with the metal bonded to the rings' π systems.

Seven people were killed in a Russian attack on the offices of Ukraine's largest printing house, located in Kharkiv. One person was killed in a separate attack in Zaporizhzhia Oblast. Russian-installed authorities in Crimea claimed that two people were killed in a Ukrainian missile attack in Simferopol Raion. The pro-Ukrainian partisan group Atesh claimed that the attack targeted a communications hub in Alushta, while other attacks were reported on a military antenna in Semydviria, Belbek airfield and in Yevpatoria. Ukraine claimed to have shot down a Russian Su-25 jet over the Donbas. Several sources questioned this claim, stating that the footage of the incident appeared to have been taken from a video game. Russia claimed to have shot down a drone over Tatarstan. Officials claimed that one person was killed in a drone strike in Belgorod Oblast. Norway pledged a $190 million military aid package to Ukraine that included support for air defense, naval capabilities, radar, anti-drone systems, and boats. Russia warned the UK that it could strike British targets "on Ukraine's territory and beyond its borders" if weapons it supplied to Ukraine are used against targets on Russian soil. The first group of Ukrainian pilots passed the US F-16 training program at Morris Air National Guard Base in Arizona and will undergo further training in Europe. Putin signed a decree allowing the assets of the United States, its citizens, and its companies to be confiscated and used for compensation for losses incurred by international sanctions.

According to various regulations, such as the international ISO 15189 norm, all pathological laboratory results must be verified by a competent professional. In some countries, staffs composed of clinical scientists do the majority of this work inside the laboratory with certain abnormal results referred to the relevant pathologist. Doctor Clinical Laboratory scientists have the responsibility for limited interpretation of testing results in their discipline in many countries. Interpretation of results can be assisted by some software in order to validate normal or non-modified results. In other testing areas, only professional medical staff (pathologist or clinical Laboratory) is involved with interpretation and consulting. Medical staff are sometimes also required in order to explain pathology results to physicians. For a simple result given by phone or to explain a technical problem, often a medical technologist or medical lab scientist can provide additional information. Medical laboratory departments in some countries are exclusively directed by a specialized Doctor laboratory Science. In others, a consultant, medical or non-medical, may be the head the department. In Europe and some other countries, Clinical Scientists with a Masters level education may be qualified to head the department. Others may have a PhD and can have an exit qualification equivalent to medical staff (e.g., FRCPath in the UK). In France, only medical staff (Pharm.D. and M.D. specialized in anatomical pathology or clinical Laboratory Science) are authorized to discuss laboratory results.

Sources: en.wikipedia.org

Reference notes

=== Insomnia === Doxepin is used in the treatment of insomnia. In 2016, the American College of Physicians advised that insomnia be treated first by treating comorbid conditions, then with cognitive behavioral therapy and behavioral changes, and then with drugs; doxepin was among those recommended for short-term help maintaining sleep, on the basis of weak evidence. The 2017 American Academy of Sleep Medicine recommendations focused on treatment with drugs were similar. A 2015 Agency for Healthcare Research and Quality review of treatments for insomnia had similar findings. A major systematic review and network meta-analysis of medications for the treatment of insomnia published in 2022 found that doxepin had an effect size (standardized mean difference (SMD)) against placebo for treatment of insomnia at 4 weeks of 0.30 (95% CITooltip confidence interval –0.05 to 0.64). The certainty of evidence was rated as very low, and no data were available for longer-term treatment (3 months). For comparison, the other sedating antihistamines assessed, trimipramine and doxylamine, had effect sizes (SMD) at 4 weeks of 0.55 (95% CI –0.11 to 1.21) (very low certainty evidence) and 0.47 (95% CI 0.06 to 0.89) (moderate certainty evidence), respectively. Benzodiazepines and Z-drugs generally showed larger effect sizes (e.g., SMDs of 0.45 to 0.83) than doxepin, whereas the effect sizes of orexin receptor antagonists, such as suvorexant, were more similar (SMDs of 0.23 to 0.44).

The Duterte administration has vowed to pursue what it describes as an "independent foreign policy" that would reject any meddling by foreign governments, reiterating Article II, Section 7 of the 1987 Constitution which states: "The State shall pursue an independent foreign policy. In its relations with other states the paramount consideration shall be national sovereignty, territorial integrity, national interest, and the right to self-determination." At a September 2016 press conference, Duterte stated: "We will observe and must insist on the time-honored principle of sovereignty, sovereign equality, non-interference and the commitment of peaceful settlements of dispute that will serve our people and protect the interests of our country." Duterte made his first international trips as president to Vientiane, Laos and Jakarta, Indonesia on September 5–9, 2016. Duterte pursued improved relations with China and Russia, and lessened the country's dependence on its traditional ally – the United States. He has adopted a cautious, pragmatic, and conciliatory stance towards China compared to his predecessor, and has set aside the previous administration's confrontational policy of asserting the Philippines' claims over the South China Sea and its islands. Militant groups decry the ties between President Duterte and China over the Chinese occupation of contested waters and the reported harassment of the fishermen amidst the territorial disputes in the South China Sea.

=== Skinny Revolution === Pickston founded Skinny Revolution to help people to lose weight after she gained 7 stone in 14 months, partly whilst pregnant, using a Wegovy (semaglutide) injection, which is a 2.4 mg injectable prescription medicine used as an appetite suppressant.

A large number of progestins, or synthetic progestogens, have been derived from progesterone. They can be categorized into several structural groups, including derivatives of retroprogesterone, 17α-hydroxyprogesterone, 17α-methylprogesterone, and 19-norprogesterone, with a respective example from each group including dydrogesterone, medroxyprogesterone acetate, medrogestone, and promegestone. The progesterone ethers quingestrone (progesterone 3-cyclopentyl enol ether) and progesterone 3-acetyl enol ether are among the only examples that do not belong to any of these groups. Another major group of progestins, the 19-nortestosterone derivatives, exemplified by norethisterone (norethindrone) and levonorgestrel, are not derived from progesterone but rather from testosterone. A variety of synthetic inhibitory neurosteroids have been derived from progesterone and its neurosteroid metabolites, allopregnanolone and pregnanolone. Examples include alfadolone, alfaxolone, ganaxolone, hydroxydione, minaxolone, and renanolone. In addition, C3 and C20 conjugates of progesterone, such as progesterone carboxymethyloxime (progesterone 3-(O-carboxymethyl)oxime; P4-3-CMO), P1-185 (progesterone 3-O-(L-valine)-E-oxime), EIDD-1723 (progesterone 20E-[O-[(phosphonooxy)methyl]oxime] sodium salt), EIDD-036 (progesterone 20-oxime; P4-20-O), and VOLT-02 (chemical structure unreleased), have been developed as water-soluble prodrugs of progesterone and its neurosteroid metabolites.

In order to measure the time-dependent viscoelastic behavior of polymers dynamic mechanical analysis is often performed. Typically, in these measurements the one side of the hydrogel is subjected to a sinusoidal load in shear mode while the applied stress is measured with a stress transducer and the change in sample length is measured with a strain transducer. One notation used to model the sinusoidal response to the periodic stress or strain is:

Sources: en.wikipedia.org

Reference notes

== Gametology == Gametology denotes the relationship between homologous genes on non-recombining, opposite sex chromosomes. The term was coined by García-Moreno and Mindell. 2000. Gametologs result from the origination of genetic sex determination and barriers to recombination between sex chromosomes. Examples of gametologs include CHDW and CHDZ in birds.

=== Negative chemical ionization === Chemical ionization for gas phase analysis is either positive or negative. Almost all neutral analytes can form positive ions through the reactions described above. In order to see a response by negative chemical ionization (NCI, also NICI), the analyte must be capable of producing a negative ion (stabilize a negative charge) for example by electron capture ionization. Because not all analytes can do this, using NCI provides a certain degree of selectivity that is not available with other, more universal ionization techniques (EI, PCI). NCI can be used for the analysis of compounds containing acidic groups or electronegative elements (especially halogens).Moreover, negative chemical ionization is more selective and demonstrates a higher sensitivity toward oxidizing agents and alkylating agents. Because of the high electronegativity of halogen atoms, NCI is a common choice for their analysis. This includes many groups of compounds, such as PCBs, pesticides, and fire retardants. Most of these compounds are environmental contaminants, thus much of the NCI analysis that takes place is done under the auspices of environmental analysis. In cases where very low limits of detection are needed, environmental toxic substances such as halogenated species, oxidizing and alkylating agents are frequently analyzed using an electron capture detector coupled to a gas chromatograph.

Taking a break from training to allow time for recovery. Reducing volume and/or intensity of training. Suitable periodization of training. Splitting the training program so that different sets of muscles are worked on different days. Increase sleep time. Deep-tissue or sports massage of the affected muscles. Self-massage or rub down of the affected muscles. Short sprints with long resting time once the athlete is able to continue with light training.

In Omega Spielhallen GmbH v Bonn a "laserdrome" business was banned by the Bonn council. It bought fake laser gun services from a UK firm called Pulsar Ltd, but residents had protested against "playing at killing" entertainment. The Court of Justice held that the German constitutional value of human dignity, which underpinned the ban, did count as a justified restriction on freedom to provide services. In Liga Portuguesa de Futebol v Santa Casa da Misericórdia de Lisboa the Court of Justice also held that the state monopoly on gambling, and a penalty for a Gibraltar firm that had sold internet gambling services, was justified to prevent fraud and gambling where people's views were highly divergent. The ban was proportionate as this was an appropriate and necessary way to tackle the serious problems of fraud that arise over the internet. In the Services Directive a group of justifications were codified in article 16, which the case law has developed.

Sources: en.wikipedia.org

Frequently asked questions

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Why is AOD-9604 discussed in anti-doping?

It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.

What did human trials of AOD-9604 find?

Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Network